Hudson Bay Capital Management LP Acquires 275,000 Shares of Genmab A/S (NASDAQ:GMAB)

Hudson Bay Capital Management LP increased its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 103.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 540,000 shares of the company's stock after purchasing an additional 275,000 shares during the quarter. Hudson Bay Capital Management LP owned approximately 0.08% of Genmab A/S worth $11,270,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Graham Capital Management L.P. grew its stake in shares of Genmab A/S by 38.2% in the fourth quarter. Graham Capital Management L.P. now owns 55,417 shares of the company's stock worth $1,157,000 after purchasing an additional 15,321 shares during the last quarter. Deep Track Capital LP bought a new stake in shares of Genmab A/S in the fourth quarter worth about $41,740,000. Cubist Systematic Strategies LLC bought a new stake in shares of Genmab A/S in the fourth quarter worth about $12,360,000. Bridger Management LLC bought a new stake in shares of Genmab A/S in the fourth quarter worth about $6,084,000. Finally, Bridgefront Capital LLC bought a new stake in shares of Genmab A/S in the fourth quarter worth about $233,000. 7.07% of the stock is owned by institutional investors.

Analyst Ratings Changes

GMAB has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Stock Up 1.2%

Shares of GMAB stock traded up $0.23 during trading hours on Friday, hitting $19.88. 836,564 shares of the company's stock traded hands, compared to its average volume of 1,112,041. The stock's fifty day simple moving average is $19.74 and its two-hundred day simple moving average is $20.75. Genmab A/S has a 12-month low of $17.24 and a 12-month high of $30.06. The stock has a market cap of $12.75 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. On average, equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.